Please check your internet connection and try again.
# Megestrol Acetate
## Overview
Megestrol acetate is a synthetic progestin derivative used primarily for its palliative effects in certain hormone-responsive cancers and to stimulate appetite.
## Primary Indications
* **Cachexia, anorexia, or unexplained weight loss:** Associated with conditions like acquired immunodeficiency syndrome (AIDS) or cancer.
* **Palliative treatment of advanced breast cancer** in postmenopausal women.
* **Palliative treatment of endometrial carcinoma.**
## Adult Dosing
* **Cachexia/Anorexia/Weight Loss:**
* Oral suspension: 625 mg orally once daily. Doses can range from 125 mg to 1250 mg daily based on patient response and tolerability.
* Oral tablets: 40 mg orally four times daily (160 mg/day) or 800 mg orally once daily.
* **Breast Cancer:** 160 mg orally once daily.
* **Endometrial Carcinoma:** 40 mg orally four times daily (160 mg/day). Treatment should continue for at least 3 months to evaluate efficacy.
## Pediatric Dosing
There is no established pediatric dosing for megestrol acetate. Use in children is generally not recommended due to potential effects on growth and development.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are recommended.
* **Hepatic Impairment:** No specific dose adjustments are recommended, but caution is advised due to potential for impaired metabolism.
## Contraindications
* Known or suspected pregnancy.
* Known hypersensitivity to megestrol acetate.
* Undiagnosed abnormal vaginal bleeding.
## Adverse Effects
* **Common:** Weight gain, abdominal pain, diarrhea, nausea, headache, hot flashes, hypertension, rash, mood changes, dyspnea.
* **Serious:** Adrenal insufficiency, thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism), hyperglycemia, tumor flare, cardiac events.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** May alter megestrol acetate concentrations.
* **Aminoglutethimide:** May decrease megestrol acetate concentrations.
* **Antidiabetic medications:** May impair glycemic control.
## Monitoring
* Weight and appetite status.
* Blood pressure.
* Signs and symptoms of thromboembolic events.
* Adrenal function (especially if prolonged therapy or signs of insufficiency).
* Blood glucose levels in diabetic patients.
* Regular gynecologic examinations for patients with endometrial carcinoma.
## Clinical Pearls
* Oral suspension is often preferred for appetite stimulation due to higher achievable doses and potentially easier administration.
* Advise patients on the risk of thromboembolic events and to report symptoms such as leg pain, swelling, chest pain, or shortness of breath immediately.
* Due to potential adrenal suppression, do not abruptly discontinue therapy, especially after prolonged use. Tapering may be necessary.
* Pregnancy testing should be performed in women of childbearing potential before initiating therapy.
***
*Disclaimer: This information is intended for clinical decision-making support and does not replace professional judgment. Always consult the most current prescribing information and relevant literature for complete details and to verify dosing and safety before administering any medication.*
